ibalizumab   

GtoPdb Ligand ID: 10208

Synonyms: Hu5A8 | ibalizumab-uiyk | TMB-355 | TMB355 | TNX-355 | Trogarzo®
ibalizumab is an approved drug (FDA (2018), EMA (2019))
Compound class: Antibody
Comment: Ibalizumab was originally reported as anti-CD4 monoclonal antibody 5A8 by Burkly et al. (1992 ) [1]. It is a non-immunosuppressive, humanised monoclonal antibody that acts as an HIV entry inhibitor [2,4]. Anti-HIV activity of TNX-355 (later to be assigned the INN ibalizumab) in patients was reported in 2004 [5].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
Bioactivity Comments
Burkly et al.'s original analysis of ibalizumab (therein named 5A8) binding to CD4 expressed on CHO cells gives an EC50 of ~1μg/ml [1].
Selectivity at other protein targets
Key to terms and symbols Click column headers to sort
Target Sp. Type Action Value Parameter Concentration range (M) Reference
CD4 Hs Antibody Binding - - - 1
[1]